Gilead Sciences, Inc. (GILD)
$
112.97
+0.41 (0.36%)
Key metrics
Financial statements
Free cash flow per share
7.5253
Market cap
139.7 Billion
Price to sales ratio
4.8391
Debt to equity
1.2679
Current ratio
1.3154
Income quality
1.5636
Average inventory
1.8 Billion
ROE
0.3294
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Gilead Sciences, Inc. is a biopharmaceutical company that specializes in the discovery, development, and commercialization of medicines addressing unmet medical needs in the United States, Europe, and internationally. The company has achieved a significant net income of $480,000,000.00 showcasing its strong financial health. The diluted EPS is $0.38 accounting for potential share dilution, which is an important metric for investors. Furthermore, the net income ratio stands at 0.02 reflecting the company's profitability margin effectively. Gilead's EBITDA is $4,434,000,000.00 serving as a key indicator of its operational profitability. Additionally, the gross profit ratio of 0.78 reflects the efficiency of the company's production and sales operations. The product portfolio includes Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla for HIV/AIDS treatment, as well as Veklury for COVID-19. Gilead also offers therapies for liver diseases, hematology, oncology, and related cell therapies. The company's collaborations with notable partners such as Arcus Biosciences, Pionyr Immunotherapeutics, and Bristol-Myers Squibb exemplify its strategic approach to innovation. Incorporated in 1987, Gilead is headquartered in Foster City, California. The stock is reasonably priced at $112.09 appealing to a broad range of investors. With a large market capitalization of $140,174,305,700.00 the company is a dominant player in the biotechnology industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth within its category. Moreover, the stock has a high average trading volume of 6,953,700.00 indicating strong liquidity, which is an essential factor for investors seeking reliable investments. By fulfilling unmet medical needs and maintaining strong financial metrics, Gilead Sciences continues to be a vital entity in its field, dedicated to providing effective solutions for serious health conditions while upholding a commitment to improvement and advancement in biopharmaceutical science.
Is Gilead Sciences, Inc. (GILD) a good investment?
Investing in Gilead Sciences, Inc. (GILD) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bearish outlook. Always conduct your own research before investing.
What is Gilead Sciences, Inc. (GILD)'s stock forecast?
Analysts predict Gilead Sciences, Inc. stock to fluctuate between $77.74 (low) and $121.83 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Gilead Sciences, Inc.'s market capitalization?
As of 2025-08-29, Gilead Sciences, Inc.'s market cap is $140,174,305,700, based on 1,240,810,000 outstanding shares.
How does Gilead Sciences, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Gilead Sciences, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Gilead Sciences, Inc. pay dividends?
Gilead Sciences, Inc. pays dividends. The current dividend yield is 2.78%, with a payout of $0.79 per share.
How can I buy Gilead Sciences, Inc. (GILD) stock?
To buy Gilead Sciences, Inc. (GILD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for GILD. Place an order (Market, Limit, etc.).
What is the best time to invest in Gilead Sciences, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Gilead Sciences, Inc. stock ever split?
Gilead Sciences, Inc.'s last stock split was 2:1 on 2013-01-28.
How did Gilead Sciences, Inc. perform in the last earnings report?
Revenue: $28,754,000,000 | EPS: $0.38 | Growth: -91.63%.
Where can I find Gilead Sciences, Inc.'s investor relations reports?
Visit https://www.gilead.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Gilead Sciences, Inc.?
You can explore historical data from here
What is the all-time high and low for Gilead Sciences, Inc. stock?
All-time high: $121.83 (2025-08-12) | All-time low: $57.17 (2022-06-14).
What are the key trends affecting Gilead Sciences, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.
reuters.com
The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV infection, the company said on Tuesday.
investors.com
Gilead Sciences won European approval Tuesday for its new twice-annual HIV prevention shot, now called Yeytuo.
businesswire.com
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company's twice-yearly injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk who weigh at least 35kg. Yeytuo is the first and only twice-yearly PrEP option to be approved for.
zacks.com
Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with Interius BioTherapeutics.
seekingalpha.com
Gilead Sciences remains a long-term Buy due to solid quarterly results, raised guidance, and continued strength in its HIV portfolio, especially Biktarvy. The recent launch of Yeztugo and a robust HIV pipeline support accelerating long-term growth, with analysts raising EPS estimates and management optimistic on margins. Despite recent gains, Gilead is still undervalued based on free cash flow and intrinsic value calculations, offering further upside potential for investors.
zacks.com
Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP launch Yeztugo.
seekingalpha.com
Gilead Sciences, Inc. (NASDAQ:GILD ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andrew D. Dickinson - Chief Financial Officer Daniel P.
seekingalpha.com
Gilead Sciences, Inc.'s HIV franchise, led by Biktarvy, ensures stable cash flows through 2033, providing long-term visibility and a strong competitive advantage. The launch of Yeztugo, a biannual PrEP injection, could significantly expand Gilead's market share and drive future revenue growth. Valuation remains attractive: GILD trades below peer multiples, boasts robust margins, and offers a sector-leading dividend yield above 2.8%.
zacks.com
Gilead Sciences (GILD) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.95 per share. This compares to earnings of $2.01 per share a year ago.
See all news
